ArticlesAssessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
Introduction
In Australia, a fully government-funded human papillomavirus (HPV) vaccination programme started in April, 2007, using the quadrivalent vaccine, which protects against HPV types 6 and 11, the main causes of most genital warts,1 and types 16 and 18, the main causes of most HPV-associated anogenital neoplasia.2 Between April, 2007, and the end of December, 2009, the programme used a catch-up strategy for girls aged 12–17 years delivered through schools and for women aged up to 26 years through community providers. Since 2009, the continuing school programme routinely vaccinates girls in the first year of high school (aged 12–13 years), and boys of the same age were added in 2013.
HPV vaccinations given in schools are systematically reported to the National HPV Vaccination Program Register,3 and on a voluntary basis from community providers. On the basis of register data, the catch-up programme achieved high coverage, with at least one dose received by 83% of girls aged 12–17 years, and three doses received by 70% (fully vaccinated).4 Women aged 18–26 years had lower coverage than the younger age group (55% received one dose and 32% received three doses).5 Findings from separate population surveys6, 7 have suggested that register-based coverage estimates for the community programme underestimated coverage by 5–15%.
Australian researchers have already reported findings about several population-based indicators of vaccine programme effectiveness, including substantial reductions in cases of genital warts diagnosed at sexual health clinics8, 9 and rates of histologically confirmed high-grade cervical lesions10 in young women in vaccinated cohorts.11, 12, 13 These reductions in HPV-related diseases strongly suggest that the population prevalence of vaccine-targeted HPV types has declined since the vaccination programme began. We provided the world's first confirmation of this decline, when we reported the results of an interim analysis of the initial 404 women enrolled into a study of HPV prevalence in young women.14 We now report on the conclusion of this study, using vaccination status validated against the vaccination register, and with the goals of more accurately measuring the magnitude of the reduction in prevalence of targeted HPV types, investigating herd immunity against infection in unvaccinated women, and assessing evidence for cross-protection in vaccinated women against genetically related HPV types.
Section snippets
Participants
As described previously,14 this study was designed as a repeat cross-sectional study to compare HPV prevalence in two samples of women, recruited from family planning clinics in three major metropolitan areas of Australia (Sydney, Melbourne, and Perth). The prevaccine-implementation sample, which was a subset of the women that we assessed in the Women, Human papillomavirus prevalence, Indigenous, Non-indigenous, Urban, Rural Study (WHINURS),15 included women aged 18–24 years who attended family
Results
During the postvaccine-implementation phase, family planning clinics recruited 1058 age-eligible (18–24 years) women whose results were compared with 202 women in the same age group recruited in the prevaccine-implementation phase. Women in the postvaccine-implementation sample were more likely to be using hormonal contraception than were women in the prevaccine-implementation sample and were slightly younger, but were similar with respect to other characteristics (table 1).
The crude prevalence
Discussion
Using a repeat cross-sectional study design and recruiting participants from clinical sites with sentinel surveillance, we have confirmed our observation from an interim analysis that a substantial reduction in prevalence of vaccine-preventable HPV genotype infections has occurred after implementation of Australia's National HPV Vaccination Program. The size, timing, and specificity of this fall suggest that it is a true biological effect of vaccination and not due to changes in sexual
References (38)
- et al.
Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey
Vaccine
(2014) - et al.
Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data
Lancet Infect Dis
(2011) - et al.
Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study
Lancet
(2011) - et al.
Human papillomavirus genotyping using a modified linear array detection protocol
J Virol Methods
(2006) - et al.
Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system
J Virol Methods
(2008) - et al.
Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England
Vaccine
(2013) - et al.
Reduction of HPV infections through vaccination among at-risk urban adolescents
Vaccine
(2012) - et al.
Sex in Australia: first experiences of vaginal intercourse and oral sex among a representative sample of adults
Aust N Z J Public Health
(2003) - et al.
Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors?
Vaccine
(2013) - et al.
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine
J Infect Dis
(2009)
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update
Int J Cancer
Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia
Sex Health
Human papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach
Med J Aust
Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18–26 years from the National HPV Vaccination Program Register
Commun Dis Intell Q Rep
Human papillomavirus vaccine national catch-up program—insights into under-notification
Aust Fam Physician
The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme
Sex Transm Infect
Cervical screening in Australia 2010–2011. AIHW cancer series, no. 76
Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia
BMJ
Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study
BMC Med
Cited by (232)
A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji
2023, The Lancet Regional Health - Western PacificAbility of epidemiological studies to monitor HPV post-vaccination dynamics: a simulation study
2023, Epidemiology and InfectionEnsuring equity with pre-clinical planning for chlamydia vaccines
2023, npj Vaccines
- †
Joint first authors